Novartis

Showing 15 posts of 819 posts found.

Novartis to acquire majority stake in Alcon

January 5, 2010
Sales and Marketing Alcon, Novartis, eye care

Novartis plans to gain a majority hold of global eye care leader Alcon, significantly boosting its presence in the sector. …

Pharma mergers and acquisitions in 2009

December 22, 2009
Research and Development, Sales and Marketing Abbott, GSK, J&J, JJ, M&A, MA, Novartis, Pfizer, Wyeth, generics, industry, merger, year in review

This year saw two ‘mega mergers’ in the sector, the acquisition of Wyeth by Pfizer and the reverse takeover of …

Novartislr

Novartis’ COPD contender cleared in EU

December 4, 2009
Sales and Marketing COPD, Novartis, resp

 Novartis has been given a green light in the European Union to sell its Onbrez respiratory drug, allowing the firm …

Incyte’s Novartis cancer drug deal could be worth $1bn

December 1, 2009
Research and Development Incyte, Novartis

Novartis has paid Incyte Corporation $150 million up front for the rights to two oral investigational hematology-oncology therapies.The first is …

Novartis opens $1bn flu vaccine plant

November 25, 2009
Manufacturing and Production Novartis, US, vaccines

Novartis has opened a new $1 billion vaccine manufacturing plant that is the first to be set up as a …

Novartis gets German OK for swine flu vaccine

November 5, 2009
Research and Development, Sales and Marketing Novartis, h1n1

 Novartis’ swine flu vaccine Celtura has been approved in Germany, its first market, in what is a major milestone for …

European approval for 3-in-1 version of Exforge

October 23, 2009
Sales and Marketing Diovan, Exforge, Novartis, cv, hypertension

European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …

New 2-in-1 Valturna outperforms Diovan

October 1, 2009
Sales and Marketing Diovan, Novartis, Tekturna, cv, hyp, hypertension

Novartis has gained US approval for a combination of its blockbuster blood pressure drug Diovan and its follow-up product Tekturna/Rasilez.Valturna …

Europe approves two swine-flu vaccines

September 30, 2009
Sales and Marketing EU, GSK, Novartis, h1n1

The European Commission has approved the use of two vaccines for the pandemic H1N1 virus, commonly known as swine flu. …

Novartis swine-flu jab effective in single dose

September 3, 2009
Manufacturing and Production, Research and Development, Sales and Marketing Novartis, h1n1

A study of Novartis' pandemic swine-flu jab shows it is potentially protective after just one dose, which could help eke …

UCB and Novartis expand alliance in Germany

September 1, 2009
Sales and Marketing Germany, Novartis, UCB

UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …

Novartis unveils new lab approach to boost research capacity

August 27, 2009
Research and Development Novartis, Switzerland

Novartis has unveiled a new research approach involving novel lab technology and flexible working, in the hope to speed its …

Novartis’ Extavia approved in US

August 19, 2009
Research and Development, Sales and Marketing Extavia, MS, Novartis

 Novartis has received US approval for its betaferon product for multiple sclerosis.Extavia’s active ingredient is interferon beta-1b, putting it into …

Animal rights attacks were terrorism not activism, says Vasella

August 13, 2009
Research and Development, Sales and Marketing Animal tests, Novartis, Vasella

Novartis chief executive Daniel Vasella has spoken for the first time of his shock at the arson attack on his …

Latest content